* Cocrystal Pharma Inc COCP.OQ reported a quarterly
adjusted
loss of 49 cents per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of -41 cents. The mean expectation of three analysts for
the quarter was for a loss of 57 cents per share. Wall Street
expected results to range from -59 cents to -55 cents per share.
* Reported revenue was zero; analysts expected zero.
* Cocrystal Pharma Inc's reported EPS for the quarter was a
loss
of 49 cents.
* The company reported a quarterly loss of $4.94 million.
* Cocrystal Pharma Inc shares had held steady so far this
quarter and gained 2.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 13.2%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Cocrystal Pharma
Inc is $7.00
This summary was machine generated from LSEG data November 13 at
03:22 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.57 -0.49 Beat
Jun. 30 2024 -0.48 -0.53 Missed
Mar. 31 2024 -0.54 -0.39 Beat
Dec. 31 2023 -0.60 -0.44 Beat